Mission 2028 on track, but Q2 organic growth lags targets
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Reaffirmed INR500Cr vision and margins; hit acquisition milestones (Aequitas, Group Pharma integrated). Missed organic growth target (9.3% vs 10%+, vs 1.5x IPM claimed). Early stage on integrations.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Clear multi-year vision (INR500Cr by FY28) backed by acquisitions + field force expansion to 10K doctors across 4 therapies. But Q2 organic growth of 9.3% undershot 10%+ guidance and 1.5x IPM target; PAT declined -2.3% YoY despite revenue growth, signaling margin compression from hospital channel integration. Execution risk is material.
₹96.4 Cr
Revenue · +29.4% YoY₹12.3 Cr
Reported PAT · −2.3% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Organic growth accelerating, 10%+ CAGR, outperforming IPM
Q2 standalone +9.3% YoY, below IPM ~12%, below stated 10% target
OVERSTATED
Maintaining 1.5x IPM growth trajectory (from Q1 call)
9.3% organic growth vs ~12% IPM = 0.78x, not 1.5x
MISS
Strong organic momentum on back of power brands and new launches
9.3% organic, margins compressed YoY, PAT down -2.3% despite revenue growth
OVERSTATED
Clear road map to INR500 crores by FY28 without further large acquisitions
Already done 2 acquisitions in 6 months (Yash Pharma, Aequitas, Group Pharma); consolidated revenue +29% but organic only +9.3%
Partially Overstated
Hospital channel integration smooth, synergies visible
Aequitas only 1 quarter old, Group Pharma 1 month old; no Q2 financials for Group Pharma; early to claim success
Unverified
Earnings quality
What changed since the last call
INR500 crores mission reaffirmed
NeutralConsistent with Q1 guidance (Jan 2026 call). No change in target, but added Group Pharma acquisition as third inorganic pillar.
Hospital channel now core strategy
UpgradeAequitas (July) + Group Pharma Wellness (Oct) acquired; now pursuing 11%+ hospital revenue mix. Prior strategy was pure Rx trade channel.
Organic growth guidance implicitly downgraded
DowngradeQ1 implied 10%+ organic target; Q2 delivered 9.3%. Claimed still 'on track' but trajectory softening vs expectations.
Field force expansion accelerating
UpgradePlan to reach ~10K doctors (from ~1.37K) to cross-sell into Aequitas institutional channel. New organizational capability vs Q1.
The Q&A
Sajal Kapoor (Antfragilis) pushed hard on organic growth miss: challenged 10% and 1.5x IPM guidance vs actual 9.3% and ~0.78x IPM delivered. Management held firm but evasive—said 'things have started looking up' without addressing why targets were missed. On 5-year vision and manufacturing backend strategy, management deferred to board/promoters. Analysts pressed on margin trajectory and brand specifics; management confident but non-specific on which brands drive Q4 recovery.
INR500 crores vision credibility — Ankur Kumar, Alpha Capital
AnsweredClear roadmap with execution. Growth faster from Q3. Investments in product, people, capabilities are setting up Q3 onwards.
Blended business EBITDA margin — Ankur Kumar, Alpha Capital
AnsweredConfident of 22% EBITDA margin at scale. Standalone will be much higher. Hospital lower (70%-80% gross margin business).
Q3 margin guidance — Ankur Kumar, Alpha Capital
AnsweredQ3 will deliver more than 22%. Q4 is drag (seasonal India). On 3-quarter basis, very close to 22% or more.
Organic growth vs IPM — Sajal Kapoor, Antfragilis Thinking
PartialMarket growing at 12% to 16.8%. We've been flattish at around 10%. Our growth will accelerate. Branded Rx upward of 10%.
Organic vs inorganic split — Sajal Kapoor, Antfragilis Thinking
AnsweredYes, we will provide it from Q3 deck onwards in commentary.
5-year vision beyond 2028 — Sajal Kapoor, Antfragilis Thinking
DodgedMission 2028 is our focus. Beyond that, in discussion with promoters/board. Will come back with more granular detail.
Aequitas rationale — Mihir Damania, Fident Asset Management
AnsweredLegacy Jagsonpal weak in hospital. Industry moved 11%+ to hospital channel. Aequitas provided niche entry, co-sell Jagsonpal brands into their channel.
Indocap/Equirex de-growth — Urmish Shah, Moneyvisers
AnsweredIndocap: legacy brand, old molecule, innovation underway (results expected Nov). Equirex: NRx-restricted, category pricing dependent. Will double-down on both.
Group Pharma business margins — Harshil Parekh, BTH Capital
AnsweredSimilar to Jagsonpal.
PAT guidance for FY28 — Gulam Soni, Individual Investor
PartialWith the sales and EBITDA margin guidance we've given, you can decipher the numbers. Do the math.
Sustainable gross margin blended business — Vansh Gupta, Prescient Capital
AnsweredStandalone is branded business, will improve 50-75 bps year-to-year. Aequitas much lower (hospital). Each follows own trajectory.
Which brands will drive Q4 growth? — Vansh Gupta, Prescient Capital
PartialTop 10 brands are 60% of revenue, will contribute majority. New brands take quarters/years to scale.
Aequitas ramp-up challenges — Vansh Gupta, Prescient Capital
AnsweredNot at all. Hospital business rate-driven, contract-based. Supply chain work ongoing, benefits from Q4.
Aequitas INR100 crores guidance — Vansh Gupta, Prescient Capital
AnsweredFor the full year, yes. Nothing changes for us.
Guidance
INR500 crores by FY28 (Mission 2028)
MediumDependent on pure organic growth (~10% CAGR on INR300Cr base) + synergies from Aequitas/Group Pharma. No further large M&A planned. Q3 to cross INR100Cr.
INR100+ crores standalone by end FY27
MediumRequires ~23% QoQ growth from INR81Cr Q2 to hit. Q3 typically strong; hospital channel ramp-up. Ambitious but stated confidently.
22% EBITDA margin at INR500Cr scale
MediumStandalone currently 22.7% H1. Hospital channel (Aequitas, Group Pharma) lower margin will drag consolidated. Confident margins sustainable once Aequitas >50% at maturity.
Standalone gross margin ~65% sustainable (improving 50-75 bps YoY)
HighCurrently 64.1%, targeting premium positioning. Hospital channel (Group Pharma 70-80% gross) will improve from supply chain synergies.
Risks the call surfaced
Organic growth shortfall
HighStandalone +9.3% YoY vs 10%+ guidance and claimed 1.5x IPM growth. Market growing ~12-16%, company growing slower. Indicates market share loss in branded Rx segment.
Hospital channel margin risk
HighAequitas (hospital/institutional) and Group Pharma (critical care) are lower-margin businesses (70%-80% gross vs 64% standalone). Will structurally depress consolidated EBITDA and PAT unless supply chain + pricing synergies realized.
Aequitas integration execution
MediumAequitas acquired July 2026 (1 quarter old); only 1 full quarter in Q2 results. Supply chain work ongoing; benefits said to accrue Q4. Early to confirm integration success; re-negotiation of contracts, pricing pressure possible.
Legacy brand de-growth persistence
MediumIndocap (GP/ortho) and Equirex (NRx-restricted dermatology) declining despite claimed innovation pipeline. Indocap older molecule, Equirex NRx-driven and restricted market. May not revive on timeline.
Field force expansion execution risk
MediumPlan to expand field force from 1.37K to 10K doctors (7.3x growth) is capex + talent heavy. New capability to support institutional channel cross-selling. Hiring, training, retention risk.
Management
Score 6/10. Confident and detailed on strategy and acquisitions. Evasive on 5-year vision and manufacturing backend questions. Deferred to board/promoters on strategic direction beyond FY28. Numbers-focused on EBITDA, vague on PAT guidance. Delivered acquisitions on plan (Aequitas July, Group Pharma Oct). Integration progressing (Aequitas 1 quarter, Group Pharma 1 month). Missed organic growth target (9.3% vs 10%+) and implicit 1.5x IPM guidance. PAT down -2.3% YoY despite revenue growth; execution not translating to bottom-line.
1 · Q3 FY27
Target INR100+ crores standalone revenue; test 23% QoQ growth claim
2 · Q4 FY27
Group Pharma wellness portfolio ramp-up; Aequitas supply chain synergies accrue
3 · Nov 2026
First value-added launch from Aequitas; test inorganic integration model
Execution risk is material.
Jagsonpal Q2: consolidated PAT ₹12.3cr; standalone profit flat YoY on margin compression
PAT +0.13% YoY · revenue +9.28% · margins compressing
₹96.37 Cr
+9.28% YoY
₹12.29 Cr
+0.13% YoY
12.46%
-3.8pp YoY
₹1.86
Jagsonpal Pharmaceuticals reported its first-ever consolidated financial results for Q2 FY27 (quarter ended 30 September 2026), following the 1 July 2026 acquisition of an 85% stake in Aequitas Healthcare. Consolidated revenue came in at ₹96.37 Cr and consolidated PAT was ₹12.29 Cr, with no like-for-like consolidated comparative available since this is the Group's debut consolidation. On the comparable standalone basis, revenue rose 9.3% YoY to ₹81.38 Cr (₹74.47 Cr in Q2 FY26) but PAT was essentially flat, up just 0.1% YoY to ₹12.59 Cr (₹12.57 Cr) — or roughly +2.0% adjusted for a ₹0.235 Cr Aequitas-related exceptional transaction cost booked this quarter and absent a year ago. Basic standalone EPS was ₹1.91 versus ₹1.88 a year earlier. Sequentially the quarter was softer: standalone revenue was down 1.0% and PAT down 4.5% against Q1 FY27's ₹82.23 Cr revenue and ₹13.19 Cr PAT.
Q2 FY-2027 vs prior quarters
The gap between YoY revenue growth (+9.3%) and roughly flat profit sits in margins: standalone NPM slipped to 15.48% from 16.23% a year ago, and OPM contracted to around 20.6% from 22.07%, as employee benefit expense rose (including a ₹35.38 Mn half-year ESOP/share-based payment charge) and D&A stepped up alongside intangible amortisation. Consolidated-period margins cannot yet be trended given the Group has no prior comparative, but the newly added hospital-segment business and its integration costs are already embedded in this quarter's base.
The stock went into the print at ₹236.2, down 2.3% over the past month of trading.
For context: revenue is at a 6-quarter high.
Maintaining 1.5x IPM growth target for FY27. Aequitas targeting ₹100 Cr revenue within 2.5 years and ₹10 Cr EBITDA by year-two post-integration. Organic growth engines (Indocap, Maintane, Endoreg) to drive acceleration in coming quarters.
— This quarter: missed
No verified Street estimate for this quarter turned up in the public domain, so the print cannot be graded beat/miss/inline, and no separate management press release was available for direct comment. Against the company's own guidance — reiterated at the Q1 FY27 call to maintain '1.5x IPM growth' — the result falls short: India's pharma market tracked roughly 10-13% YoY value growth through mid-to-late 2026 per Pharmarack data, above Jagsonpal's 9.3% standalone revenue growth, let alone 1.5x of it. Corporate activity was heavier than the P&L this quarter: the Board completed the ₹20.8 Cr Aequitas acquisition (85% stake, hospital-segment entry) effective 1 July, signed a separate ₹46.7 Cr Business Transfer Agreement with Group Pharmaceuticals for its wellness portfolio on 23 September (completed only in October, so no P&L impact yet), paid a ₹4/share (₹26.38 Cr) final FY26 dividend, and executed a ₹40.1 Cr equity buyback during the half — funded from the company's own bank-deposit balance rather than debt.
W1
Wellness Portfolio acquisition (₹46.7 Cr, closed October 2026) — first quarter it shows up in revenue/margins is Q3 FY27.
W2
Aequitas Healthcare's progress toward management's stated ₹100 Cr revenue (within 2.5 years) and ₹10 Cr EBITDA (by year two) targets, now in its first full consolidated quarter.
W3
Standalone margin trajectory — OPM at ~20.6% and NPM at 15.48% this quarter, both down YoY and QoQ; watch whether cost growth (ESOP, Labour Code-related employee benefit changes flagged in the notes) stabilises.